BioNTech and Pfizer have secured approval from the German regulatory authority, Paul-Ehrlich-Institut, to conduct a Phase I/II clinical trial of a Covid-19 vaccine candidate.
The candidate, BioNTech’s BNT162, is intended to prevent Covid-19 infection. BioNTech and Pfizer are co-develping the vaccine programme.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Said to be the first Covid-19 vaccine trial to launch in Germany, the study is part of a global development programme.
